Literature DB >> 16880294

Number of cervical biopsies and sensitivity of colposcopy.

Julia C Gage1, Vivien W Hanson, Kim Abbey, Susan Dippery, Susi Gardner, Janet Kubota, Mark Schiffman, Diane Solomon, Jose Jeronimo.   

Abstract

OBJECTIVE: To examine the influence that type of medical training and number of biopsies have on sensitivity of colposcopically guided biopsies.
METHODS: Among 408 women with an adequate enrollment colposcopy and a diagnosis of cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN 3+) over 2 years in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions (ASCUS-LSIL) Triage Study, we evaluated factors influencing the sensitivity of the enrollment colposcopic procedure. We used contingency table analysis to examine confounding variables and chi(2) tests to ascertain statistical significance.
RESULTS: Overall, 69.9% of women with a cumulative diagnosis of CIN 3+ had a "true-positive" enrollment colposcopically guided biopsy result of CIN 2 or worse (CIN 2+), the threshold that would trigger excisional therapy. The sensitivity of the procedure did not vary significantly by type of colposcopist. However, the sensitivity was significantly greater when the colposcopists took two or more biopsies instead of one (P<.01), a pattern observed across all types of colposcopists. Independent of the severity of the colposcopic impression, the frequency with which colposcopists took two or more biopsies instead of one varied (in descending order) from nurse practitioners to general gynecologists to gynecologic oncology fellows to gynecologic oncologists (P<.01).
CONCLUSION: Colposcopy with guided biopsy or biopsies detects approximately two thirds of CIN 3+. Although the sensitivity of the procedure does not differ significantly by type of medical training, it is greater when two or more biopsies are taken.

Entities:  

Mesh:

Year:  2006        PMID: 16880294     DOI: 10.1097/01.AOG.0000220505.18525.85

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  80 in total

1.  Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Authors:  Nicole G Campos; Philip E Castle; Mark Schiffman; Jane J Kim
Journal:  Med Decis Making       Date:  2011-12-06       Impact factor: 2.583

2.  [Colposcopy in the diagnosis of early cervical cancer].

Authors:  W Kühn
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 3.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

Review 4.  Conservative management of adolescents with abnormal cytology and histology.

Authors:  Anna-Barbara Moscicki
Journal:  J Natl Compr Canc Netw       Date:  2008-01       Impact factor: 11.908

5.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

6.  [Correlation of cervical cytology and histology].

Authors:  K Marquardt
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

7.  ASCCP Colposcopy Standards: Colposcopy Quality Improvement Recommendations for the United States.

Authors:  Edward J Mayeaux; Akiva P Novetsky; David Chelmow; Francisco Garcia; Kim Choma; Angela H Liu; Theognosia Papasozomenos; Mark H Einstein; L Stewart Massad; Nicolas Wentzensen; Alan G Waxman; Christine Conageski; Michelle J Khan; Warner K Huh
Journal:  J Low Genit Tract Dis       Date:  2017-10       Impact factor: 1.925

8.  Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

Authors:  Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2014-02-25       Impact factor: 5.226

9.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

10.  Accuracy of cervical specimens obtained for biomarker studies in women with CIN3.

Authors:  Nicolas Wentzensen; Rosemary E Zuna; Mark E Sherman; Michael A Gold; Mark Schiffman; S Terence Dunn; Jose Jeronimo; Roy Zhang; Joan Walker; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2009-09-20       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.